TScan Therapeutics, Inc. (TCRX) News
Follow TScan Therapeutics, Inc. (TCRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
TScan Therapeutics cut to Neutral from Buy by HC Wainwright
HC Wainwright & Co. downgraded TScan Therapeutics to Neutral from Buy, according to Benzinga ratings actions cited by TradingView News.
EQUITY | Sep 08, 2026, 03:25 PM UTC
L
TScan Therapeutics price target cut to $1.00 from $5.00
Wedbush cut its price target on TScan Therapeutics to $1.00 per share from $5.00, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 01:19 PM UTC
L
TScan Therapeutics cut to Hold from Buy by Needham
Needham downgraded TScan Therapeutics to Hold from Buy, per Benzinga ratings actions.
EQUITY | Sep 03, 2026, 09:16 AM UTC
M
U.S. factory orders rise 0.9% in July, topping estimates
U.S. factory orders rose 0.9% month-over-month in July, compared with estimates for a 0.7% gain.
MACRO | Sep 02, 2026, 04:01 PM UTC
M
TCRX in vivo TCR therapies move to IND-enabling stage
TCRX says two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities. Preclinical data and regulatory updates are expected in Q1 2027, with a phase I trial planned for Q4 2027.
EQUITY | Sep 02, 2026, 02:39 PM UTC
M
TCRX advances solid-tumor TCR programs to IND-enabling stage
TCRX said two in vivo solid-tumor TCR therapies (PRAME, MAGE-A4) moved to IND-enabling stage with clinical trials planned for late 2027. Heme and autoimmune efforts are paused; financial runway extended into Q4 2027.
EQUITY | Sep 02, 2026, 01:38 PM UTC
M
TCRX TSC-101 reports 79% 6-month relapse-free survival in post-HCT
TSC-101 in high-risk post-HCT patients showed 79% relapse-free survival at 6 months, with safety also reported in the heme program.
EQUITY | Sep 02, 2026, 11:58 AM UTC
L
TScan terminates CFO and CMO in strategic reorganization
TScan terminated CFO Jason A. Amello and CMO Chrystal Louis as part of a strategic reorganization, and CEO Gavin MacBeath assumed principal financial and accounting officer duties effective September 2, 2026.
REGULATION | Sep 02, 2026, 11:24 AM UTC
L
TScan Therapeutics gets Nasdaq notice over $1 minimum bid
Nasdaq notified the company that its common stock failed the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1) for 30 consecutive trading days. Trading continues on Nasdaq Global Market; 180 days to Feb.
EQUITY | Sep 02, 2026, 11:24 AM UTC
M
TCRX shifts focus to in vivo TCR-T solid tumor programs
TCRX says a reorganization will advance two in vivo TCR-T solid tumor candidates to IND-enabling studies and plan Phase 1 trials in late 2027, while pausing or seeking partners for heme malignancy and autoimmune programs
EQUITY | Sep 02, 2026, 11:13 AM UTC
L
TScan Therapeutics announces reorganization to focus on solid-tumor cell therapy
TScan Therapeutics says it will reorganize to focus on in vivo cell therapy for solid tumors.
EQUITY | Sep 02, 2026, 11:02 AM UTC
L
TCRX Reports Q2 2026 Financial Results
TScan Therapeutics reports second quarter 2026 financial results and provides corporate update
EARNINGS | Aug 12, 2026, 11:00 AM UTC
H
TCRX doses first patient
TScan starts Phase 3 trial
EQUITY | Jul 29, 2026, 11:01 AM UTC
M
TCRX: Moves to Phase 3
TScan's cancer therapy data supports move to Phase 3 trial
EQUITY | Jun 22, 2026, 11:10 AM UTC
H
TCRX: Reports Positive Data
TScan Therapeutics announces positive initial data from cohort C of ongoing ALLOHA Phase 1 study evaluating TSC-101
EQUITY | Jun 22, 2026, 11:00 AM UTC